In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ception Therapeutics

Latest From Ception Therapeutics

Teva's Reslizumab Faces FDA Questions On Breadth Of Asthma Indication

Clinical development program's inclusion criteria encompassed moderate-to-severe asthmatics but actually only studied patients with severe disease.

BioPharmaceutical United States

BioNotebook: After selling to Actelion, entrepreneur Tullman starts new company, and Revance, Dicerna, UniQure file for IPOs

Steve Tullman, the serial biopharma entrepreneur who sold companies to Actelion, Allergan and Cephalon in the past few years, is starting a new company, Alexar Therapeutics. Malvern, Pennsylvania-based Alexar is being formed with $21.5 million in financing raised by Mr Tullman’s firm NeXeption. In September, another Tullman company, Ceptaris Therapeutics, was sold to Actelion for $250 million.


Actelion, Under Pressure To Diversify, Eyes Rare Disease Start-Up Ceptaris

Actelion is paying a $25 million upfront for an option to acquire Ceptaris Therapeutics, contingent upon the latter’s receiving FDA approval for its only asset, Valchlor, which faces an August PDUFA date. If the deal closes, Ceptaris will receive another $225 million plus milestones from the Swiss-based biotech.

BioPharmaceutical Deals

On The Respiratory Horizon: A Wave Of Biologics For Asthma

Several antibody drugs are in late-stage development to treat severe asthma and could reach the market in the next two years. But competition for niche subsets of patients will be fierce, and tailoring the right medications to the right patients to justify the higher cost of treatment will require advances in biomarker development.

BioPharmaceutical Clinical Trials
See All

Company Information